뒤로
Cue Biopharma Inc (CUE) 수입
CUE 주가 차트
CUE 수입
Cue Biopharma Inc
$0.26
3.64%
$0
종가: Mar 25, 16:00:00 GMT-4
$0.25
-5.22%
$-0.01
애프터마켓: Mar 25, 20:00:00 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
CUE의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Cue Biopharma Inc CUE의 지난 분기 매출 실적은 어땠나요?
Cue Biopharma Inc의 매출 추정치는 얼마인가요?
Cue Biopharma Inc의 수익 품질 점수는 얼마인가요?
Cue Biopharma Inc는 언제 수익을 보고하나요?
Cue Biopharma Inc의 예상 수익은 얼마인가요?
Cue Biopharma Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.2549
시가
$0.261
일일 범위
$0.25 - $0.269
52주 범위
$0.23 - $1.05
거래량
621.0K
평균 거래량
1.7M
배당수익률
--
EPS(TTM)
-0.46
시가총액
$19.7M
CUE란 무엇인가요?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.